How to manage Waldenstrom's macroglobulinemia

Leukemia

Volumn 27, Issue 4, 2013, Pages 762-772

  Buske, C ^a   Leblond, V ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

diagnosis; prognostification; treatment; Waldenstrom's macroglobulinemia

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; PENTOSTATIN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ALLOTRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; DRUG EFFICACY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

AGED; HUMANS; PROGNOSIS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84876149674     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.36     Document Type: Review

References (84)

1. Waldenström J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia-a new syndrome? Acta Med Scand 1944; 117: 216-247.
2. Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni Jr JF. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998; 82: 1078-1081.
3. Phekoo KJ, Jack RH, Davies E, Moller H, Schey SA. The incidence and survival of Waldenstrom's macroglobulinaemia in South East England. Leuk Res 2008; 32: 55-59.
4. Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC et al. 6q Deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007; 136: 80-86.
5. Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström macroglobulinemia. Haematologica 2012, in press.
6. Poulain S, Braggio E, Roumier C, Aijjou R, Broucqsault N, Galiegue-Zouitina S et al. High-throughput genomic analysis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11: 106-108.
7. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
8. Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013; 27: 183-189.
9. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012; 367: 2255-2256 author reply 2256-7.
10. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012; 367: 826-833.
11. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108: 2755-2763.
12. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM et al. Epigenetic modifications as key regulators of Waldenstrom's macroglobulinemia biology. J Hematol Oncol 2010; 3: 38.
13. Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006; 17: 488-494.
14. Kristinsson SY, Koshiol J, Goldin LR, Bjorkholm M, Turesson I, Gridley G et al. Genetics-and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9: 23-26.
15. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008.
16. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110-115.
17. Pasricha SR, Juneja SK, Westerman DA, Came NA. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia. J Clin Pathol 2011; 64: 520-523.
18. San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, Sanchez ML et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 187-195.
19. Schuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol 2010; 85: 853-855.
20. Ghobrial IM. Are you sure this is Waldenstrom macroglobulinemia? Hematology Am Soc Hematol Educ Program 2012; 2012: 586-594.
21. Avet-Loiseau H, Garand R, Lode L, Robillard N, Bataille R. 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 153-155.
22. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013; 160: 171-176.
23. Menke MN, Feke GT, McMeel JW, Treon SP. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9: 100-103.
24. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113: 4163-4170.
25. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009; 27: 120-126.
26. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 116-120.
27. Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23: 153-161.
28. Abonour R, Zhang L, Rajkumar V, Srkalovic G, Greipp P, Fonseca R et al. Phase II pilot study of rituximab\+CHOP in patients with newly diagnosed WM, an ECOG Study (E1A02). Blood 2007; 110: 3616a.
29. Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Turnbull B et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9: 62-66.
30. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25: 3344-3349.
31. Zinzani PL, Gherlinzoni F, Bendandi M, Zaccaria A, Aitini E, Salvucci M et al. Fludarabine treatment in resistant Waldenstrom's macroglobulinemia. Eur J Haematol 1995; 54: 120-123.
32. Leblond V, Choquet S. Fludarabine in Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 239-242.
33. Leblond V, Levy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 2001; 98: 2640-2644.
34. Dimopoulos MA, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 1993; 95: 49-52.
35. Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 2009; 113: 793-796.
36. Tamburini J, Levy V, Chaleteix C, Fermand JP, Delmer A, Stalniewicz L et al. Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia 2005; 19: 1831-1834.
37. Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P et al. Rituximab and subcutaneous 2-chloro-20-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010; 28: 2233-2238.
38. Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27: 3830-3835.
39. Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2005; 6: 136-139.
40. Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012; 118: 434-443.
41. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27: 250-255.
42. Leleu X, Tamburini J, Roccaro A, Morel P, Soumerai J, Levy V et al. Balancing risk versus benefit in the treatment of Waldenstrom's macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma 2009; 9: 71-73.
43. Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 2013; 31: 301-307.
44. Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C et al. Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL. Blood 2009; 144: 405.
45. Rummel M, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. JCO 2012; 30(Suppl.) abstract 3.
46. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13: 3320-3325.
47. Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1570-1575.
48. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005; 90: 1655-1658.
49. Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1422-1428.
50. Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol 2010; 85: 670-674.
51. Dimopoulos MA, Zomas A, Viniou NA, Grigoraki V, Galani E, Matsouka C et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 2001; 19: 3596-3601.
52. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112: 4452-4457.
53. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009; 15: 355-360.
54. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108: 737-742.
55. Gertz MA, Merlini G, SP Treon. Amyloidosis and Waldenstrom's macroglobulinemia. Hematology (Am Soc Hematol Educ Program) 2004 257-282.
56. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101: 2593-2598.
57. Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Options Neurol 2010; 12: 71-83.
58. Gruson B, Ghomari K, Beaumont M, Garidi R, Just A, Merle P et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst 2011; 16: 180-185.
59. Berentsen S. How I manage cold agglutinin disease. Br J Haematol 2011; 153: 309-317.
60. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85: 824-833.
61. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204-210.
62. Gertz MA, Reeder CB, Kyle RA, Ansell SM. Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant 2011; 47: 1147-1153.
63. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 2227-2232.
64. Gertz MA, Hayman SR, Buadi FK. Transplantation for IgM amyloidosis and IgM myeloma. Clin Lymphoma Myeloma 2009; 9: 77-79.
65. Kyriakou C, Canals C, Cornelissen JJ, Socie G, Willemze R, Ifrah N et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 4926-4934.
66. Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845-854.
67. Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica 2010; 95: 950-955.
68. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007; 109: 4964-4972.
69. Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve H et al. A multicenter phase II study of single-agent enzastaurin in previously treated waldenstrom macroglobulinemia. Clin Cancer Res 2012; 18: 5043-5050.
70. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007; 110: 4417-4426.
71. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1408-1414.
72. Treon SP, Tripsas CK, Ioakimidis L, Warren D, Patterson C, Heffner L et al. Prospective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia. Blood 2011; 118: abstract 2951.
73. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010; 16: 1033-1041.
74. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 2009; 113: 4391-4402.
75. Sun JY, Xu L, Tseng H, Ciccarelli B, Fulciniti M, Hunter ZR et al. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11: 152-156.
76. Ghobrial IM, Poon T, Rourke M, Chuma S, Kunsman J, Banwait R et al. Phase II trial of single agent panobinostat (LBH589) in relapsed or relapsed/refractory Waldesntrom's macroglobulinemia. Blood 2010; 116: abstract 3952.
77. Dimopoulos MA, Tsatalas C, Zomas A, Hamilos G, Panayiotidis P, Margaritis D et al. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003; 30: 265-269.
78. Furman RR, Eradat H, DiRienzo CG, Hayman SR, Hofmeister CC, Avignon NA et al. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia. Blood 2011; 118: 3701.
79. Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B et al. Longterm follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 2011; 118: 276-281.
80. Treon SP, Hanzis C, Manning RJ, Ioakimidis L, Patterson CJ, Hunter ZR et al. Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 2011; 154: 357-362.
81. Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009; 113: 3673-3678.
82. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 243-247.
83. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 2005; 6: 131-135.
84. Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F et al. Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood 2013, in press.